Trial Details
Not RecruitingBasic Information
| Clinical ID | c3185 |
|---|---|
| Identifier | EUCTR2011-005846-36-DK |
| Trial Title | Safe evaluation of obstructive crohns disease using bloodflow Time-intensity curves and Elastography correlated to Neutrocytes and collagen counts and biomechanical properties Obtained in Stenotic Intestine after Surgery (STENOSIS) - STENOSIS |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Crohns Disease undergoing elective surgery for intestinal stenosis. MedDRA version: 14.1_Level: PT_Classification code 10058829_Term: Elective surgery_System Organ Class: 10042613 - Surgical and medical procedures_ MedDRA version: 14.1_Level: PT_Classification code 10059696_Term: Scan with contrast_System Organ Class: 10022891 - Investigations_ MedDRA version: 14.1_Level: PT_Classification code 10011401_Term: Crohn's disease_System Organ Class: 10017947 - Gastrointestinal disorders_ MedDRA version: 14.1_Level: LLT_Classification code 10028049_Term: MRI_System Organ Class: 10022891 - Investigations_ MedDRA version: 14.1_Level: PT_Classification code 10045434_Term: Ultrasound scan_System Organ Class: 10022891 - Investigations_ MedDRA version: 14.1_Level: PT_Classification code 10022699_Term: Intestinal stenosis_System Organ Class: 10017947 - Gastrointestinal disorders_;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
| Interventions | Trade Name: SonoVue Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: sulphur hexafluoride CAS Number: 2551-62-4 Other descriptive name: SULFUR HEXAFLUORIDE Concentration unit: l/ml microlitre(s)/millilitre Concentration type: equal Concentration number: 8- |
Participant Information
| Sponsor | Gastroenterology MIDT |
|---|---|
| City | - |
| Country/Region | Denmark |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional clinical trial of medicinal product |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |